… relacorilant plus nab-paclitaxel and bevacizumab evaluating … with relacorilant and nab-paclitaxel improved patients’ progression- … two medications – nab-paclitaxel and bevacizumab – will … ’s syndrome) and prostate cancer. Relacorilant is proprietary to …

… by approximately 50% in a prostate cancer animal model. The study demonstrated … -induced toxicity when combined with Paclitaxel. Contrary to concerns that telomere …

… by approximately 50% in a prostate cancer animal model with aggressive cancer … and mortality when combined with Paclitaxel—a widely used chemotherapy but … For Antibacterial Treatment, Tissue Regeneration Paclitaxel and other chemotherapy agents induce …

… prostate tumors in the bone microenvironment. Mesenchymal stem cells induce already disseminated prostate cancer … facilitating metastatic prostate tumor growth in … stem cells into prostate tumours promotes metastasis. … inhibitor, and paclitaxel in patients …

… trial of relacorilant plus nab-paclitaxel in patients with platinum- … in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with … hypercortisolism (Cushing’s syndrome) and prostate cancer. Relacorilant is proprietary to Corcept …

… paclitaxel, glucose-paclitaxel, total paclitaxel over time after glucose-paclitaxel … paclitaxel over time after paclitaxel solution or glucose-paclitaxel … paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol … neuroendocrine prostate cancer. …

… de novo metastatic hormone-sensitive prostate cancer. Data for overall survival ( … trial, which combined Truqap with paclitaxel, found no significant OS benefit … patients with metastatic castration-resistant prostate cancer (mCRPC) versus Xtandi alone. These …

… making inroads in a prostate cancer subtype. High-level … -sensitive prostate cancer (mHSPC), a specific type of prostate cancer with … with metastatic castration-resistant prostate cancer (mCRPC) with PTEN … of Truqap and chemotherapy paclitaxel were roughly the …

… refractory metastatic Castration-Resistant Prostate Cancer (mCRPC). Based … preclinical activity in prostate cancer models against both … in combination with paclitaxel for the treatment … with metastatic castration-resistant prostate cancer (NCT05156905), and …

… modification of engineered exosomes. Paclitaxel (PTX), a common … cancer, the encapsulation of paclitaxel (PTX) within exosomes … a promising tool for prostate cancer diagnosis. Lab Chip. … exosomes for targeted paclitaxel delivery to pulmonary metastases …